1201643-82-4

Upstream product

• 129488-74-0 4-(1-cyano-1-methylethyl)benzoic acid 
• 1201643-80-2 2-(4-((5-bromo-1-tosyl-1H-indol-3-yl)methyl)phenyl)-2-methylpropanenitrile 
• 1201643-78-8 2-(4-(5-bromo-1-tosyl-1H-indol-3-carbonyl)phenyl)-2-methylpropanenitrile 
• 1201643-79-9 2-(4-((5-bromo-1-tosyl-1H-indol-3-yl)(hydroxy)methyl)phenyl)-2-methylpropanenitrile 
• 40119-34-4 2-methyl-2-(4-methylphenyl)propionitrile 
• 96546-77-9 N-tosyl-5-bromoindole 
• 10075-50-0 5-bromo-1H-indole 
• 1201643-81-3 2-(4-((5-bromo-1H-indol-3-yl)methyl)phenyl)-2-methylpropanenitrile 

Downstream Products

• 1201643-83-5 2-(4-(2-(2-amino-5-bromophenyl)-2-oxoethyl)phenyl)-2-methylpropanenitrile 
• 1201646-86-7 2-(4-(8-bromoisothiazolo[5,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201646-83-4 2-(4-(8-bromoisothiazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201646-79-8 2-(4-(8-bromoisoxazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201643-77-7 2-(4-((3-amino-6-bromoquinolin-4-yl)methyl)phenyl)-2-methylpropanenitrile 
• 1201646-77-6 2-(4-(8-bromoisoxazolo[5,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201645-82-0 2-(4-(8-bromo-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201646-70-9 2-(4-(3-amino-6-bromoquinolin-4-carbonyl)phenyl)-2-methylpropanenitrile 
• 1201646-73-2 2-(4-(9-bromopyrimido[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201643-85-7 2-(4-((6-bromo-3-nitroquinolin-4-yl)methyl)phenyl)-2-methylpropanenitrile 
• 1201646-75-4 2-(4-(6-bromo-3-hydroxyquinolin-4-carbonyl)phenyl)-2-methylpropanenitrile 
• 1201643-84-6 (E)-2-(4-(2-(5-bromo-2-(2-nitroethylideneamino)phenyl)-2-oxoethyl)phenyl)-2-methylpropanenitrile 
• 1201646-85-6 2-(4-(6-bromo-3-thiocyanatoquinolin-4-carbonyl)phenyl)-2-methylpropanenitrile 
• 1201646-76-5 2-(4-((6-bromo-3-hydroxyquinolin-4-yl)(hydroxyimino)methyl)phenyl)-2-methylpropanenitrile 

Relevant academic research and scientific papers

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.